CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
用于嵌合抗原受体治疗的单个核细胞单采采集
英文原题：Apheresis collection of mononuclear cells for chimeric-antigen receptor therapies.
查看英文原题
Apheresis collection of mononuclear cells for chimeric-antigen receptor therapies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
在过去几年中，随着商业产品的获批，用于治疗血液恶性肿瘤的经基因修饰淋巴细胞采集量急剧增加。正在开发中的可能治疗实体器官恶性肿瘤的新产品报道代表了该领域的巨大变革。血液分离术处于这些嵌合抗原受体治疗产品制造所需细胞采集的核心。这些采集的扩展代表了血液分离术操作增长的领域之一。本综述将总结对此类采集重要的概念以及需要优化的变量，以在提高患者安全性的同时获得所需的细胞产量。
展开英文摘要原文
Collections of lymphocytes to be genetically modified to treat hematologic malignancies have seen a dramatic increase over the last few years as commercial products have been approved. Reports of new products in development that can possibly treat solid organ malignancies represent a massive change in the field.
Apheresis is at the center of the collection of cells for the manufacture of these chimeric-antigen receptor therapy products. The expansion of these collections represents one of the areas of apheresis procedures growth. This review will summarize concepts important to this type of collection and variables that need to be optimized to obtain desired cell yields while increasing patients' safety.
论文信息
- 作者
- Maitta RW
- 单位
- Department of Pathology, University Hospitals Cleveland Medical Center and Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.United States
- 文献类型
- 综述
- 期刊
- European journal of haematology2024 Jan
- 原文标识
- PubMed 37525900 · DOI 10.1111/ejh.14071